1. Home
  2. ORIC vs KRSA Comparison

ORIC vs KRSA Comparison

Compare ORIC & KRSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oric Pharmaceuticals Inc.

ORIC

Oric Pharmaceuticals Inc.

HOLD

Current Price

$7.61

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Korsana Biosciences Inc. Common Stock

KRSA

Korsana Biosciences Inc. Common Stock

N/A

Current Price

$32.37

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ORIC
KRSA
Founded
2014
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
ORIC
KRSA
Price
$7.61
$32.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
6
Target Price
$21.79
★ $44.00
AVG Volume (30 Days)
★ 1.8M
167.5K
Earning Date
11-16-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 19.67
8.26
EPS
★ N/A
N/A
Revenue
N/A
★ $2,074,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 3.70
52 Week Low
$7.23
$29.03
52 Week High
$14.68
$37.27

Technical Indicators

Market Signals
Indicator
ORIC
KRSA
Relative Strength Index (RSI) 30.56 51.99
Support Level $7.40 $29.67
Resistance Level $14.23 $34.51
Average True Range (ATR) 0.70 1.87
MACD -0.10 0.21
Stochastic Oscillator 1.97 62.45

Price Performance

Historical Comparison
ORIC
KRSA

About ORIC Oric Pharmaceuticals Inc.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

About KRSA Korsana Biosciences Inc. Common Stock

Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.

Share on Social Networks: